Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study

World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management

(2012) Jason Gotlib   AMERICAN JOURNAL OF HEMATOLOGY

Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation

(2012) Grzegorz Helbig et al.   AMERICAN JOURNAL OF HEMATOLOGY

Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT and against FGFR1-derived fusion kinases

(2012) E Lierman et al.   LEUKEMIA

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

(2012) F J Giles et al.   LEUKEMIA

Nilotinib and Imatinib Are Comparably Effective in Reducing Growth of Human Eosinophil Leukemia Cells in a Newly Established Xenograft Model

(2012) Daniel Wicklein et al.   PLoS One

Treatment of Hypereosinophilic Syndromes—The First 100 Years

(2012) J.H. Butterfield et al.   SEMINARS IN HEMATOLOGY

ICON

(2012) Peter Valent et al.   World Allergy Organization Journal

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease

(2011) C. Elling et al.   BLOOD

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

(2011) J. E. Cortes et al.   BLOOD

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation

(2011) G Metzgeroth et al.   LEUKEMIA

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

(2011) F J Giles et al.   LEUKEMIA

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

(2011) P D le Coutre et al.   LEUKEMIA

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

(2010) Paul W. Manley et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence

(2010) Martin M. Crane et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib

(2010) Takayuki Ikezoe et al.   LEUKEMIA RESEARCH

Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome

(2010) Emeline Tabouret et al.   LEUKEMIA RESEARCH

Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations

(2009) F. Roufosse   HAEMATOLOGICA

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome

(2009) Joseph H. Butterfield   LEUKEMIA RESEARCH

Fibroblast Growth Factor Receptor and Platelet-Derived Growth Factor Receptor Abnormalities in Eosinophilic Myeloproliferative Disorders

(2008) Nicholas C.P. Cross et al.   ACTA HAEMATOLOGICA

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome - a phase-II study

(2008) Georgia Metzgeroth et al.   BRITISH JOURNAL OF HAEMATOLOGY

Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia

(2008) S. Verstovsek et al.   CLINICAL CANCER RESEARCH

Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRα

(2008) Christian Baumgartner et al.   EXPERIMENTAL HEMATOLOGY

Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

(2008) J Gotlib et al.   LEUKEMIA

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

(2008) Marc E. Rothenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE